Article info

PDF

Original research article
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction

Authors

  1. Correspondence to Rola Haroun, Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland; Rola.Haroun{at}novartis.com
View Full Text

Citation

McMurray JJV, Trueman D, Hancock E, et al
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction

Publication history

  • Received 22 September 2016
  • Revised 25 October 2017
  • Accepted 2 November 2017
  • Published online 8 February 2018.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.